Elsevier’s Clinical Pharmacology Now Accessible Through Elsevier Infobutton
TAMPA, Florida, November 28, 2012 /PRNewswire/ –
Elsevier Infobutton now links from EHRs to key content in Clinical
Elsevier’s Gold Standard [http://www.goldstandard.com ], a leading drug information
provider, announced today that its Clinical Pharmacology drug reference solution will be
accessible through the recently launched Elsevier Infobutton [http://www.elsinfobutton.com
], a one-touch service that links from an EHR (electronic health record) to evidence-based
content in Elsevier electronic information solutions. Institutions with an EHR can license
and then link to Elsevier’s comprehensive drug reference content in Clinical Pharmacology
through clinical terms in the patient record.
The Elsevier Infobutton helps providers achieve EHR certification for Stage 2
Meaningful Use by supporting these HL7 (Health Level Seven International) Infobutton
standard use cases:
- Context--sensitive links that reference information to support clinical decision-making - Links to patient-specific education resources
is trusted by more than 2,000 hospitals nationwide and is accepted as a professional
drug reference by all 50 State Boards of Pharmacy.
“The Elsevier Infobutton demonstrates real value at the point-of-care by simplifying
access to clinical decision support information and patient education materials that
improve care and patient outcomes,” said Marianne Messer, President, Elsevier’s Gold
Standard. “Our goal continues to focus on providing solutions that elevate the standard of
care through easily-accessible, user-friendly, evidence-based drug information.”
The Elsevier Infobutton is offered free-of-charge to customers with an EHR who also
license other Elsevier electronic information products, including Clinical Pharmacology,
Mosby’s Nursing Consult and Mosby’s Skills.
For more information about Elsevier Infobutton please visit
About Elsevier’s Gold Standard
Based in Tampa, FL, Elsevier’s Gold Standard uses innovative technologies to provide a
complete suite of drug information and decision support solutions. With a tenacious
commitment to product quality, Elsevier’s Gold Standard solutions empower healthcare
organizations, professionals and consumers to meet the most pressing healthcare
challenges, improve patient safety and ensure optimal outcomes. To learn more about
Elsevier’s Gold Standard, visit http://www.goldstandard.com.
Elsevier is a world-leading provider of scientific, technical and medical information
products and services. The company works in partnership with the global science and health
communities to publish more than 2,000 journals, including The Lancet
[http://www.thelancet.com ] and Cell [http://www.cell.com ], and close to 20,000 book
titles, including major reference works from Mosby and Saunders. Elsevier’s online
solutions include ScienceDirect [http://www.sciencedirect.com ], Scopus
[http://www.scopus.com ], Reaxys [http://www.reaxys.com ], ClinicalKey
[http://www.clinicalkey.com ] and Mosby’s Nursing Suite [http://www.confidenceconnected.com
], which enhance the productivity of science and health professionals, and the SciVal
suite [http://www.scival.com ] and MEDai’s Pinpoint Review [http://www.medai.com ], which
help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier [http://www.elsevier.com ]
employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC
[http://www.reedelsevier.com ], a world-leading publisher and information provider, which
is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN
(Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media contact Christopher Capot Director, Corporate Relations Elsevier +1-212-633-3164 firstname.lastname@example.org